Point72 Asset Management's Schedule 13G Filing for Aptevo Therapeutics Inc.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 9.1% of the common stock of Aptevo Therapeutics Inc. The filing, dated September 16, 2025, indicates that Point72 Asset Management maintains investment and voting power over the shares held by Point72 Associates, LLC. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. The filing is made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934. The address of the principal business office for all reporting persons is 72 Cummings Point Road, Stamford, CT 06902. The filing includes a Joint Filing Agreement as Exhibit 99.1.